Vivos Therapeutics Sees Major Revenue Increase in Q3 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2025
0mins
Should l Buy VVOS?
Source: Newsfilter
Financial Performance: Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the acquisition of the Sleep Center of Nevada, with total revenue reaching $6.8 million for the quarter and $13.6 million for the nine months ended September 30, 2025.
Strategic Shift: The company is transitioning from a dental distribution model to direct affiliations and acquisitions of medical sleep practices, which is expected to enhance revenue streams and meet growing patient demand in the Las Vegas area.
Operational Challenges: Operating expenses increased by 74% to $8.7 million in Q3 2025 due to investments in personnel and infrastructure related to the SCN acquisition, leading to a higher operating loss of $4.7 million for the quarter.
Future Plans: Vivos is exploring additional market expansions and partnerships, including a management agreement with MISleep Solutions in Michigan, while continuing to optimize operations at SCN to reduce cash burn and aim for profitability in 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VVOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VVOS
Wall Street analysts forecast VVOS stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.974
Low
2.50
Averages
5.00
High
7.00
Current: 0.974
Low
2.50
Averages
5.00
High
7.00
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vivos Therapeutics Reports 16% Revenue Growth in 2025
- Revenue Growth: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by the acquisition of the Sleep Center of Nevada (SCN) and increased sleep testing services, enhancing its market competitiveness.
- Gross Profit Increase: The company achieved a gross profit of $10.5 million in 2025, a 17% increase from 2024, maintaining a consistent gross margin of 60%, indicating effective cost control and business integration.
- Rising Operating Expenses: Operating expenses surged to $30.4 million in 2025 from $20.2 million in 2024, primarily due to increased general and administrative costs associated with the new business model, reflecting financial pressure during the transition.
- Widening Net Loss: Vivos Therapeutics reported a net loss of $21.2 million for 2025, reflecting high costs associated with strategic transitions, while facing provider shortages that led to revenue declines, impacting overall financial health.
See More
Vivos Therapeutics Reports Increased Annual Loss
- Increased Annual Loss: Vivos Therapeutics reported a full-year loss of $21.17 million, translating to a loss of $2.07 per share, which is a deterioration compared to last year's loss of $11.14 million and $2.22 per share, indicating worsening financial health.
- Revenue Growth: Despite the increased losses, the company's revenue rose by 16% to $17.44 million from $15.03 million last year, suggesting that Vivos still possesses some sales capability in the market.
- Earnings Per Share Comparison: The loss per share improved slightly from $2.22 last year to $2.07, indicating a reduction in losses; however, it still reflects ongoing challenges faced by the company in reversing its overall financial performance.
- Market Reaction: Given the persistent losses and financial pressures, investors may adopt a cautious stance regarding the company's future prospects, potentially impacting its stock price performance and market confidence.
See More
Vivos Therapeutics Q4 2025 Earnings Call Insights
- Revenue Growth and Challenges: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by a $4.8 million boost in sleep testing services, although a decline in legacy program revenues is expected, indicating both challenges and opportunities in the new operational model.
- Operating Costs and Profitability Pressure: The company achieved a gross profit of $10.5 million with a consistent gross margin of 60%, yet operating expenses surged to $30.4 million, resulting in a net loss of $21.2 million, reflecting financial pressures and ongoing funding needs amid expansion efforts.
- Market Access and Staffing Bottlenecks: CEO Huntsman highlighted that SCN's expansion is constrained by physical space, provider numbers, and third-party payer credentialing issues, emphasizing that these factors will directly impact future revenue growth and competitive positioning in the market.
- Future Outlook and Financing Needs: Management aims for cash flow positive operations by the end of 2026, yet must continue to secure equity financing to comply with NASDAQ's minimum stockholders' equity requirements, illustrating the balancing act between rapid expansion and financial stability.
See More
Vivos Therapeutics Reports Disappointing Earnings
- Disappointing Earnings: Vivos Therapeutics reported a FY GAAP EPS of -$2.07, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company generated $17.44M in revenue, a 16.0% year-over-year increase, yet fell short of expectations by $3.27M, suggesting that despite growth, it failed to meet market forecasts, potentially impacting future financing capabilities.
- Cash Position: As of December 31, 2025, Vivos had $2.0M in cash and cash equivalents, which was subsequently bolstered by two financing transactions totaling $6.8M, improving liquidity but raising concerns about the sustainability of cash flow.
- Financing Activities: Vivos Therapeutics announced the exercise of warrants for gross proceeds of $4.64M, a move that helps strengthen the company's financial position, yet the long-term strategic implications of this funding remain to be assessed.
See More
VIVOS THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE FULL YEAR 2025
Financial Performance: Vivos Therapeutics reported its financial results for the year 2025, highlighting key metrics and performance indicators.
Market Position: The report outlines Vivos' strategic initiatives and market positioning within the therapeutic sector, emphasizing growth opportunities and challenges.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
Vivos Therapeutics Reports 16% Revenue Growth in 2025
- Revenue Growth: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by the acquisition of the Sleep Center of Nevada (SCN) and increased sleep testing services, enhancing its market competitiveness.
- Gross Profit Increase: The company achieved a gross profit of $10.5 million in 2025, a 17% increase from 2024, maintaining a consistent gross margin of 60%, indicating effective cost control and business integration.
- Rising Operating Expenses: Operating expenses surged to $30.4 million in 2025 from $20.2 million in 2024, primarily due to increased general and administrative costs associated with the new business model, reflecting financial pressure during the transition.
- Widening Net Loss: Vivos Therapeutics reported a net loss of $21.2 million for 2025, reflecting high costs associated with strategic transitions, while facing provider shortages that led to revenue declines, impacting overall financial health.
See More
Vivos Therapeutics Reports Increased Annual Loss
- Increased Annual Loss: Vivos Therapeutics reported a full-year loss of $21.17 million, translating to a loss of $2.07 per share, which is a deterioration compared to last year's loss of $11.14 million and $2.22 per share, indicating worsening financial health.
- Revenue Growth: Despite the increased losses, the company's revenue rose by 16% to $17.44 million from $15.03 million last year, suggesting that Vivos still possesses some sales capability in the market.
- Earnings Per Share Comparison: The loss per share improved slightly from $2.22 last year to $2.07, indicating a reduction in losses; however, it still reflects ongoing challenges faced by the company in reversing its overall financial performance.
- Market Reaction: Given the persistent losses and financial pressures, investors may adopt a cautious stance regarding the company's future prospects, potentially impacting its stock price performance and market confidence.
See More
Vivos Therapeutics Q4 2025 Earnings Call Insights
- Revenue Growth and Challenges: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by a $4.8 million boost in sleep testing services, although a decline in legacy program revenues is expected, indicating both challenges and opportunities in the new operational model.
- Operating Costs and Profitability Pressure: The company achieved a gross profit of $10.5 million with a consistent gross margin of 60%, yet operating expenses surged to $30.4 million, resulting in a net loss of $21.2 million, reflecting financial pressures and ongoing funding needs amid expansion efforts.
- Market Access and Staffing Bottlenecks: CEO Huntsman highlighted that SCN's expansion is constrained by physical space, provider numbers, and third-party payer credentialing issues, emphasizing that these factors will directly impact future revenue growth and competitive positioning in the market.
- Future Outlook and Financing Needs: Management aims for cash flow positive operations by the end of 2026, yet must continue to secure equity financing to comply with NASDAQ's minimum stockholders' equity requirements, illustrating the balancing act between rapid expansion and financial stability.
See More
Vivos Therapeutics Reports Disappointing Earnings
- Disappointing Earnings: Vivos Therapeutics reported a FY GAAP EPS of -$2.07, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company generated $17.44M in revenue, a 16.0% year-over-year increase, yet fell short of expectations by $3.27M, suggesting that despite growth, it failed to meet market forecasts, potentially impacting future financing capabilities.
- Cash Position: As of December 31, 2025, Vivos had $2.0M in cash and cash equivalents, which was subsequently bolstered by two financing transactions totaling $6.8M, improving liquidity but raising concerns about the sustainability of cash flow.
- Financing Activities: Vivos Therapeutics announced the exercise of warrants for gross proceeds of $4.64M, a move that helps strengthen the company's financial position, yet the long-term strategic implications of this funding remain to be assessed.
See More
VIVOS THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE FULL YEAR 2025
Financial Performance: Vivos Therapeutics reported its financial results for the year 2025, highlighting key metrics and performance indicators.
Market Position: The report outlines Vivos' strategic initiatives and market positioning within the therapeutic sector, emphasizing growth opportunities and challenges.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
